From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy